2-oxo-3-(2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionic acid ethyl ester | 152712-45-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-oxo-3-(2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionic acid ethyl ester
• 英文别名: ethyl 2-oxo-3-(2,3,4,5-tetrahydro-1-benzazepin-1-yl)propanoate
• CAS: 152712-45-3
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: RPIVPFMDPSSYCR-UHFFFAOYSA-N

物化性质

• 沸点：
  402.6±28.0 °C(predicted)
• 密度：
  1.122±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-oxo-3-(2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionic acid ethyl ester 在 喹啉 、 sodium hydroxide 、 copper chromite 、 magnesium chloride 作用下， 以 四氢呋喃 、 乙醇 、 乙二醇甲醚 为溶剂， 反应 11.0h， 生成 4,5,6,7-tetrahydro-azepino<3,2,1-hi>indole
  参考文献：
  名称：

  Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annulated indole derivatives. 1

  摘要：

  On the basis of the structures of ondansetron and GR 65,630, its ring-opened C-linked methylimidazole analogue, novel 1,7-annelated indole derivatives were synthesized as potential 5-HT3 antagonists. Receptor binding studies show that all compounds display a high affinity for the 5-HT3 receptors. In both series annelation results in compounds being 7 and 4 times more potent than the references ondansetron and GR 65,630, respectively. Similar to ondansetron, the 1,7-annelated indoles show little stereoselectivity. The (-)-isomers are only slightly more potent than the (+)-isomers. The receptor binding profile of l-10-[(2-methyl-1H-imidazol-1-yl)methyl]-5,6,8,9,10,11-hexahydro-4H-pyrido[3,2,1-jk]carbazol-11-one hydrochloride (24b) (INN cilansetron) shows that the compound displays, besides a high affinity for 5-HT3 receptors (K(i) = 0. 19 nM), a weak affinity for sigma-receptors (K(i) = 340 nM), muscarine M1 receptors (K(i) = 910 nM), and 5-HT4 receptors (K(i_ = 960 nM) and no affinity (K(i) greater-than-or-equal-to 5000 nM) for all the other receptor types tested (n = 37). The new compounds fit the proposed necessary chemical template for binding: a heteroaromatic ring system, a coplanar carbonyl group, and a nitrogen center at well-defined distances. The enhanced potency of the annelated 1,7-indole derivatives indicates that the extra ring provides a favorable hydrophobic area for interaction with the 5-HT3 receptor site. In vivo cilansetron is more potent and induces less central side effects than ondansetron. At present cilansetron is in clinical trials.

  DOI：

  10.1021/jm00075a026
• 作为产物：
  描述：

  3-溴丙酮酸乙酯 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 7.67h， 以40%的产率得到2-oxo-3-(2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionic acid ethyl ester
  参考文献：
  名称：

  [EN] PURINE DERIVATIVES AS KINASE INHIBITORS
  [FR] DERIVES DE LA PURINE EN TANT QU'INHIBITEURS DE LA KINASE

  摘要：

  本发明提供了化合物I的激酶抑制剂。

  公开号：

  WO2003076442A1

文献信息

• Agents and methods for the treatment of proliferative diseases
  申请人：——

  公开号：US20030229026A1

  公开（公告）日：2003-12-11

  The present invention provides selective kinase inhibitors of formula (I). 1

  这项发明提供了式（I）的选择性激酶抑制剂。
• Purine derivatives as kinase inhibitors
  申请人：Engler Albert Thomas

  公开号：US20050090483A1

  公开（公告）日：2005-04-28

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了式I的激酶抑制剂。
• Agents and method for the treatment of proliferative diseases
  申请人：——

  公开号：US20030092676A1

  公开（公告）日：2003-05-15

  1 The present invention provides selective kinase inhibitors of formula (I).

  本发明提供了式(I)的选择性激酶抑制剂。
• PURINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Engler Thomas Albert

  公开号：US20090105229A1

  公开（公告）日：2009-04-23

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了化合物I的激酶抑制剂。
• Medicaments useful for the treatment of proliferative diseases
  申请人：ELI LILLY AND COMPANY

  公开号：EP1250334B1

  公开（公告）日：2004-05-19